The role of pharmacologic treatment to prevent sudden death in the implantable cardioverter defibrillator era

Current Cardiology Reports

Volumn 3, Issue 2, 2001, Pages 167-172

  Elliott, Perry M ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT;

COMPARATIVE STUDY; DEFIBRILLATOR; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; REVIEW; SUDDEN DEATH;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN; DEFIBRILLATORS, IMPLANTABLE; HUMANS;

EID: 0035290979     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-001-0045-6     Document Type: Article

References (46)

1. Shah PM, Adelman AG, Wigle ED, et al.: The natural and unnatural history of hypertrophic obstructive cardiomyopathy. Circ Res 1974, 35(suppl II):179-195.
2. Loogen F, Kuhn H, Gietzen F, et al.: Clinical course and prognosis of patients with typical and atypical hypertrophic obstructive and with hypertrophic non-obstructive cardiomyopathy. Eur Heart J 1983, 4(suppl F):145-153.
3. McKenna WJ, Deanfield J, Faruqui A, et al.: Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and haemodynamic features. Am J Cardiol 1981, 47:532-538.
4. Koga Y, Itaya K, Toshima H: Prognosis in hypertrophic cardiomyopathy. Am Heart J 1984, 108:351-359.
5. Shapiro LM, Zezulka A: Hypertrophic cardiomyopathy: a common disease with a good prognosis. Five year experience of a district general hospital. Br Heart J 1983, 50:530-533.
6. Spirito P, Chiarella F, Carratino L, et al.: Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med 1989, 320:749-755.
7. Romeo F, Pelliccia F, Cristofani R, et al.: Hypertrophic cardiomyopathy: Is a left ventricular outflow tract gradient a major prognostic determinant? Eur Heart J 1990, 11:233-240.
8. Kofflard MJ, Waldstein DJ, Vos J, ten Cate F: Prognosis in hypertrophic cardiomyopathy observed in a large clinic population. Am J Cardiol 1993, 72:939-943.
9. Cecchi F, Olivotto I, Montereggi A, et al.: Hypertrophic cardiomyopathy in Tuscany: Clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995, 26:1529-1536.
10. Cannan CR, Reeder GS, Bailey KR, et al.: Natural history of hypertrophic cardiomyopathy. A population based study, 1976 through 1990. Circulation 1995, 92:2488-2495.
11. Maron BJ, Casey SA, Poliac LC, et al.: Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999, 17, 281:650-655.
12. Maron BJ, Olivotto I, Spirito P, et al.: Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000, 102:858-864.
13. Stafford WJ, Trohman RG, Bilsker M, et al.: Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy. J Am Coll Cardiol 1986, 7:701-704.
14. Maron BJ, Robert WC, Epstein SE: Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation 1982, 65:1388-1394.
15. Maron BJ, Shen W-K, Link MS, et al.: Efficacy of Implantable cardioverter-defibrillators for the prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000, 342:365-373.
16. Silka MJ, Kron J, Dunnigan A, Dick M: Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. Circulation 1993, 87:800-807.
17. Primo J, Geelen P, Brugada J, et al.: Hypertrophic cardiomyopathy: Role of the implantable cardioverter defibrillator. J Am Coll Cardiol 1998, 31:1081-1085.
18. Kron J, Oliver RP, Norsted S, Silka MJ: The automatic implantable cardioverter-defibrillator in young patients. J Am Coll Cardiol 1990, 16:896-902.
19. Charlier R, Delaunois G, Bauthier J, Deltour G: Dans la série des benzofurannes XI. Propriétés antiarrhythmiques de l'amiodarone [French]. Cardiologia 1969, 54:83-90.
20. Vaughan-Williams EM: A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharm 1984, 24:129-147.
21. Holt DW, Tucker GT, Jackson PR, Storey GCA: Amiodarone pharmacokinetics. Am Heart J 1983, 106:840-847.
22. Adams PC, Holt DW, Storey GCA, et al.: Amiodarone and its desethyl metabolite: tissue distribution and morphological changes during chronic therapy. Circulation 1985, 7:1064-1075.
23. Singh BN, Vaughan-Williams EM: The effect of amiodarone, new antianginal agent, on cardiac muscle. Brit J Pharm 1970, 39:657-667.
24. Singh BN: When is QT prolongation antiarrhythmic and when is it proarrhythmic? Am J Cardiol 1989, 63:867-869.
25. Vorperian VR, Havighurst TC, Miller S, January CT: Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997, 30:791-798.
26. Loh K-C: Amiodarone-induced thyroid disorders: a clinical review. Postgrad Med J 2000, 76:133-140.
27. Manicardi V, Bertorelli G, Pesci A, Bellodi G: Low dose amiodarone-induced pneumonitis: evidence of an immunologic pathogenetic mechanism. Am J Med 1989, 86:134-135.
28. Elliott PM, Rosano GMC, Gill JS, et al.: Changes in coronary sinus pH during dipyridamole stress in patients with hypertrophic cardiomyopathy. Heart 1996, 75:179-183.
29. Cannon RO, Dilsizian V, O'Gara P, et al.: Myocardial metabolic, hemodynamic, and electrocardiographic significance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy. Circulation 1991, 83:1660-1667.
30. Kennedy JA, Unger SA, Horowitz JD: Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 1996, 52:273-280.
31. Robinson K, Frenneaux MP, Stockins B, et al.: Atrial fibrillation in hypertrophic cardiomyopathy: A longitudinal study. J Am Coll Cardiol 1990, 15:1279-1285.
32. Olivotto I, Cecchi F, Santoro G, et al.: Atrial fibrillation is an important determinant of outcome in patients with hypertrophic cardiomyopathy [abstract]. Eur Heart J 1999, A225:16.
33. Pollick C: Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl Med 1982, 307:997-999.
34. Dovai H, Nul D, Grancelli H, et al.: Gruppo de Estudio de la Sobrevida en la Insuficiencia en Argentina (GESICA). Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994, 344:493-498.
35. Massie BM, Fisher SG, Radford M, et al.: Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators. Circulation 1996, 93:2128-2134.
36. Julian DG, Camm AJ, Frangin G, et al.: Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarction Amiodarone Trial Investigators. Lancet 1997, 349:667-674.
37. Cairns JA, Connolly SJ, Roberts R, Gent M: Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997, 349:675-682.
38. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF: Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985, 53:412-416.
39. Cecchi F, Olivotto I, Montereggi A, et al.: Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. Heart 1998, 79:331-336.
40. Fananapazir L, Leon MB, Bonow RO, et al.: Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am J Cardiol 1991, 67:169-174.
41. Cecchi F, Maron BJ, Epstein SE: Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol 1989, 13:1283-1288.
42. Elliott PM, Sharma S, Varnava A, et al.: Survival following cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999, 33:1596-1601.
43. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators: A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997, 337:1576-1583.
44. Buxton A, Lee KL, Fisher JD, et al. for the MUSTT Investigators: A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999, 341:1882-1890.
45. Elliott PM, Poloniecki J, Dickie S, et al.: Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000, in press.
46. Herbst JH, Goodman M, Feldstein S, Reilly JM: Health-related quality-of-life assessment of patients with life-threatening ventricular arrhythmias. Pacing Clin Electrophysiol 1999, 22:915-926.